GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cizzle Biotechnology Holdings PLC (LSE:CIZ) » Definitions » Shares Outstanding (EOP)

Cizzle Biotechnology Holdings (LSE:CIZ) Shares Outstanding (EOP) : 363.84 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Cizzle Biotechnology Holdings Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Cizzle Biotechnology Holdings's shares outstanding for the quarter that ended in Jun. 2023 was 363.84 Mil.

Cizzle Biotechnology Holdings's quarterly shares outstanding increased from Dec. 2022 (339.80 Mil) to Jun. 2023 (363.84 Mil). It means Cizzle Biotechnology Holdings issued new shares from Dec. 2022 to Jun. 2023 .

Cizzle Biotechnology Holdings's annual shares outstanding increased from Dec. 2021 (253.45 Mil) to Dec. 2022 (339.80 Mil). It means Cizzle Biotechnology Holdings issued new shares from Dec. 2021 to Dec. 2022 .


Cizzle Biotechnology Holdings Shares Outstanding (EOP) Historical Data

The historical data trend for Cizzle Biotechnology Holdings's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cizzle Biotechnology Holdings Shares Outstanding (EOP) Chart

Cizzle Biotechnology Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,070.41 253.45 12.41 253.45 339.80

Cizzle Biotechnology Holdings Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 253.45 253.45 314.11 339.80 363.84

Competitive Comparison of Cizzle Biotechnology Holdings's Shares Outstanding (EOP)

For the Biotechnology subindustry, Cizzle Biotechnology Holdings's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cizzle Biotechnology Holdings's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cizzle Biotechnology Holdings's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Cizzle Biotechnology Holdings's Shares Outstanding (EOP) falls into.



Cizzle Biotechnology Holdings Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Cizzle Biotechnology Holdings  (LSE:CIZ) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Cizzle Biotechnology Holdings Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Cizzle Biotechnology Holdings's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Cizzle Biotechnology Holdings (LSE:CIZ) Business Description

Traded in Other Exchanges
N/A
Address
C/o SGH Secretaries Limited, 60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Cizzle Biotechnology Holdings PLC is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is highly correlated with early stage lung cancer.

Cizzle Biotechnology Holdings (LSE:CIZ) Headlines

No Headlines